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Aims Nearly 60% of the world’s population lives in Asia but little is known about the characteristics and outcomes of Asian
patients with heart failure with reduced ejection fraction (HFrEF) compared to other areas of the world.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
We pooled two, large, global trials, with similar design, in 13174 patients with HFrEF (patient distribution: China 833,
India 1390, Japan 209, Korea 223, Philippines 223, Taiwan 199 and Thailand 95, Western Europe 3521, Eastern Europe
4758, North America 613, and Latin America 1110). Asian patients were younger (55.0–63.9 years) than in Western
Europe (67.9 years) and North America (66.6 years). Diuretics and devices were used less, and digoxin used more,
in Asia. Mineralocorticoid receptor antagonist use was higher in China (66.3%), the Philippines (64.1%) and Latin
America (62.8%) compared to Europe and North America (range 32.8% to 49.6%). The rate of cardiovascular
death/heart failure hospitalization was higher in Asia (e.g. Taiwan 17.2, China 14.9 per 100 patient-years) than
in Western Europe (10.4) and North America (12.8). However, the adjusted risk of cardiovascular death was higher
in many Asian countries than in Western Europe (except Japan) and the risk of heart failure hospitalization was lower
in India and in the Philippines than in Western Europe, but significantly higher in China, Japan, and Taiwan.
*Corresponding author. British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK. Tel: +44 141 330 3479,
Fax: +44 141 330 6955, Email: john.mcmurray@glasgow.ac.uk
A complete list of the PARADIGM-HF and ATMOSPHERE investigators is provided in the online supplementary Appendix S1.
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
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Conclusion Patient characteristics and outcomes vary between Asia and other regions and between Asian countries. These
variations may reflect several factors, including geography, climate and environment, diet and lifestyle, health care
systems, genetics and socioeconomic influences.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Although heart failure is a global problem afflicting approximately
30million people worldwide, little is known about how the char-
acteristics of affected individuals, clinical outcomes and response
to treatment vary outside Europe and North America.1 Yet, nearly
60% of the world’s population lives in Asia, with China and India
alone constituting about 37% of the global population. The future
importance of Asia in relation to the globalization of clinical tri-
als has been highlighted recently and the differences in individual
characteristics between Asian and other patients, and among Asian
patients, have begun to be described, although largely in hospi-
talized individuals apart from the Chronic Heart Failure Analy-
sis and Registry in the Tohoku District 2 (CHART-2) study and
most recently, the Asian Sudden Cardiac Death in Heart Failure
(ASIAN-HF) registry.2–8 Little, however, is known about ambula-
tory patients with heart failure in the two largest countries in Asia
and long-term clinical outcomes have not been compared within
Asia and between Asia and the rest of the world. The Prospective
comparison of ARNI with ACEI to Determine Impact on Global
Mortality and morbidity in Heart Failure (PARADIGM-HF) and the
Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE
(ATMOSPHERE) trials were the largest and most globally repre-
sentative trials ever conducted in patients with heart failure and
reduced ejection fraction (HFrEF).9,10 These two trials had almost
identical inclusion and exclusion criteria and a common control
group treated with enalapril. We have pooled these two recent
trial datasets to examine clinical characteristics and patient out-
comes in Asian countries compared to the other major regions of
the world.
Methods
Design of included trials and participants
The inclusion and exclusion criteria of the two trials were almost
identical.11,12 Briefly, patients were eligible at screening if they were
≥18 years of age, had New York Heart Association (NYHA) func-
tional class II–IV, left ventricular ejection fraction (LVEF) ≤ 35%
(changed from ≤ 40% initially in PARADIGM-HF by amendment), ele-
vated natriuretic peptides (cut-off level independent of atrial fibril-
lation), and took an angiotensin-converting enzyme (ACE) inhibitor
or angiotensin receptor blocker (ARB), along with a beta-blocker
(unless contraindicated or not tolerated) and a mineralocorticoid
receptor antagonist (MRA), if indicated. Exclusion criteria at screen-
ing included symptomatic hypotension or systolic blood pressure
< 95mmHg (< 90mmHg in ATMOSPHERE), estimated glomerular fil-
tration rate (eGFR) < 30 (< 35 in ATMOSPHERE) mL/min/1.73m2
and potassium > 5.4 (> 5.2 in ATMOSPHERE) mmol/L. The trial was ..
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. approved by ethics committees at all 1043 participating centres in 47
countries in PARADIGM-HF and 789 centres in 43 countries in ATMO-
SPHERE, and all patients provided written informed consent.
On trial entry, ongoing therapy with an ACE inhibitor or ARB
was stopped and patients entered a sequential run-in, first receiv-
ing enalapril followed by sacubitril/valsartan in PARADIGM-HF and
enalapril followed by the combination of enalapril plus aliskiren in
ATMOSPHERE. Patients tolerating both run-in periods were randomly
assigned to double-blind therapy with sacubitril/valsartan or enalapril
in a 1:1 ratio in PARADIGM-HF or enalapril, aliskiren or both drugs in
a 1:1:1 ratio in ATMOSPHERE.9,10
Outcomes
The primary outcome of both trials was a composite of death from car-
diovascular causes or heart failure hospitalization. In the present study,
we investigated the association between country/region and risk of the
primary outcome, each of its components and all-cause mortality. All
endpoints were adjudicated by the same clinical endpoint committee
according to pre-specified criteria.
Countries/regions of interest
The Asian countries which enrolled at least 90 patients in the two trials
were China (including Hong Kong), India, Japan, Korea, Philippines,
Taiwan and Thailand; these were compared to the regions of Western
Europe (reference region), Eastern Europe, North America and Latin
America.
In both trials, patients were asked to self-identify their race (as one
of: Caucasian, Black, Asian, Native American, Pacific Islander, or other)
and ethnicity (as one of: Hispanic/Latino, Chinese, Indian, Japanese,
mixed ethnicity, other or unknown). Only Caucasians were included
in the analysis of non-Asian regions (Caucasians constituted 76% of all
individuals in these regions).
Statistical analysis
Baseline characteristics are presented as means with standard devi-
ations or medians with interquartile ranges for continuous variables
and frequencies and percentages for categorical variables. Differences
in baseline characteristics according to country/region at baseline were
assessed using the chi-square test for categorical variables and either
ANOVA or the Kruskal–Wallis test for continuous variables.
Incidence rates for the outcomes of interest are presented per
100 patient-years. Relative hazard ratios (HR) with 95% confidence
intervals of outcomes according to country/region were calculated
using Cox proportional hazard models using Western Europe as the
reference group. Final models included adjustment for randomized
treatment (enalapril, sacubitril/valsartan, aliskiren, or combination of
enalapril and aliskiren), and the following baseline characteristics: age,
sex, heart rate, systolic blood pressure, body mass index (BMI),
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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N-terminal pro B-type natriuretic peptide (NT-proBNP), LVEF, eGFR
and NYHA class. The primary outcome and its composites were also
tested for competing risks of death using Fine–Gray sub-distribution
hazard model. We also carried out a sensitivity analysis by adjusting for
variables in the Meta-Analysis Global Group in Chronic Heart Failure
(MAGGIC) risk score.13
Analyses were performed using Stata version 14.0 (Stata Corp.,
College Station, TX, USA). Two-sided P-values < 0.05 were considered
significant.
Results
Of the 13174 patients included in this analysis, 833 (6.3%) were
resident in China, 1390 (10.6%) in India, 209 (1.6%) in Japan,
223 (1.7%) in Korea, 223 (1.7%) in the Philippines, 199 (1.5%)
in Taiwan, and 95 (0.7%) in Thailand; 3521 (26.7%) participants lived
in Western Europe (reference region), 4758 (36.1%) in Eastern
Europe, 613 (4.7%) in North America, and 1110 (8.4%) in Latin
America (Table 1). All patients enrolled in China and Japan were
of Chinese or Japanese ethnicity, respectively; those in the other
Asian countries were of ‘other’ or ‘mixed’ Asian ethnicity except
for Taiwan where 167 were of Chinese ethnicity and 32 of ‘other’
Asian ethnicity.
Baseline characteristics: patients in Asia
compared with those elsewhere
Except for those in Japan (mean age 63.9 years), Asian patients were
considerably younger on average (55.0–61.2 years) than Western
European (mean age 67.9 years) and North American patients
(66.6 years).
Asian patients had a lower BMI (range 22.9–25.6 kg/m2) than
those in other regions (e.g. 27.8 kg/m2 in Western Europe and
29.8 kg/m2 in North America) and a lower systolic blood pressure
than in Europe (although not lower than in North or Latin Amer-
ica). With the exceptions of India, Taiwan and the Philippines, Asian
patients had a lower prevalence of diabetes than those in Europe
and North America (although not Latin America); the same pat-
tern was seen for hypertension (although this was as common in
Latin America as in Europe and North America).
Chronic obstructive pulmonary disease (COPD) was much
less common in most Asian countries (Taiwan was the notable
exception) than in Europe and North America (but not Latin
America). This was despite current smoking being a lot more
common in many Asian countries. As with COPD, renal disease
was much less common in most Asian countries (except Taiwan),
and Latin America, compared with Europe and North America.
The prevalence of atrial fibrillation (on an electrocardiogram) was
lower in most Asian countries and strikingly lower in India (2.5%)
than in Europe or the Americas (14.8–36.7%).
Looking at heart failure characteristics, an ischaemic aetiology
was less common in most Asian countries (e.g. 33.3% in China) than
in other regions, although was as common in India (69.7%) and the
Philippines (66.4%) as in Europe (57.4% in Western and 70.9% in
Eastern Europe) and North America (71.8%). Asian patients were
generally less severely functionally limited, according to NYHA ..
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.. class, except those in China and India. Consistent with this, patients
in Asian countries had higher (better) Kansas City Cardiomyopaty
Questionnaire (KCCQ) scores than in Europe and the Americas.
LVEF was generally lower in patients in Asian countries compared
with Europe and, to a lesser extent, North America. NT-proBNP
levels were at least as high in China (1470 pg/mL) and the Philip-
pines (2241 pg/mL) (and nearly as high in India and Thailand) as
in Europe (1381 pg/mL Western Europe, 1454 pg/mL in Eastern
Europe) and the Americas but markedly lower in other Asian coun-
tries (e.g. median 1263 pg/mL in Taiwan and 943 pg/mL in Korea).
History of pre-randomization heart failure hospitalization varied
markedly across the world with the greatest variation within Asia,
from 43.7% in India to 76.9% in Taiwan (the range in Europe and
the Americas was 58.8–68.2%) (Table 2).
In terms of symptoms and signs, patients in Asia generally
(Taiwan being the exception) had less evidence of congestion
(oedema, raised jugular venous pressure) than those in Europe
and North America (with Latin America again more like Asia).
Pre-trial use of an ARB (rather than ACE inhibitor) was higher in
most Asian countries (ranging from 13.8% in China to 53.4% in the
Philippines) than in Europe and the Americas (10.4–11.4%), with
the exceptions of Japan (4.8%), Thailand (8.4%) and India (10.0%).
In terms of laboratory and other investigations, creatinine and
haemoglobin varied considerably among countries/regions without
a definite pattern. The lowest average haemoglobin was in India
(127 g/L) and highest in the Philippines (143 g/L), compared with
139–142 g/L in Europe and the Americas. Left bundle branch
block was less prevalent in most Asian countries than elsewhere.
Consistent with this, average QRS duration was shorter in Asia
than in the other regions (although QRS duration was shorter in
Eastern Europe than in the other non-Asian regions).
On examination of treatments used, diuretics were less com-
monly taken by patients in most Asian countries, compared with
elsewhere (with the exceptions of India and Japan). Conversely, use
of digoxin was much more common (except in Japan). Beta-blocker
use was uniformly high globally, although was lower in India, the
Philippines and Taiwan than elsewhere. MRA prescription var-
ied greatly, with the highest use in China (66.3%) the Philippines
(64.1%) and Latin America (62.8%) compared with other countries
and regions (range 32.8–49.6% in Europe and North America).
Use of anticoagulants was lower in most Asian countries (as low
as 5.1% in India and 7.8% in China). Device use was low overall
but much less in all Asian countries than in Western Europe and
North America (device use was also uncommon in Latin America
and Eastern Europe) (Table 3).
Outcomes: patients in Asia compared
with those elsewhere
With respect to the primary composite outcome, patients
in Taiwan (17.2 per 100 patient-years), China (14.9), and Thai-
land (13.8) had a higher event rate than those in Europe (10.4
in Western and 12.3 in Eastern Europe) and the Americas (12.8
in North and 12.6 in Latin America) and the adjusted risk was
significantly higher in these Asian countries than in Western
Europe, the reference region. However, the picture was quite
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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different when the components of the composite were exam-
ined separately. The adjusted risk of cardiovascular death was
higher in India, China, the Philippines, Thailand and Taiwan, than
in Western Europe, whereas the risk of this outcome tended
to be lower in patients in Japan (Table 4). A broadly similar pattern
was observed for all-cause mortality (with a significantly lower
all-cause mortality in Japan than in Western Europe). Conversely,
the risk of hospital admission was significantly lower in India and
in the Philippines than in Western Europe, whereas this risk was
significantly higher in China, Japan, and Taiwan (Table 4, Figure 1
and online supplementary Table S1).
Discussion
Together, the patients enrolled in PARADIGM-HF and ATMO-
SPHERE comprise the largest, most contemporary and most
geographically, racially and ethnically diverse cohort of patients
with HFrEF enrolled in clinical trials, with participants from 55
countries. In the present analyses we focused on 3172 patients
enrolled from seven countries in Asia, including 1390 from India
and 833 from China. We believe this to be the only report describ-
ing long-term non-fatal and fatal outcomes in HFrEF patients in Asia
and comparing these with other regions of the world.
Although our analysis was by country, it should be noted that
this geographical division of patients was largely synonymous with
their categorization by race and ethnicity. For example, all patients
in China, India and Japan were reported to be of Asian race but to
have Chinese, Indian or Japanese ethnicity, respectively. All patients
in the remaining Asian countries were described as of Asian race
and, in most cases, ‘other’ ethnicity. The one exception was Taiwan
where most patients described themselves as having Chinese
ethnicity. Very small numbers of participants in the comparator
regions were of Asian race.
We found substantial differences among patients within coun-
tries in Asia and between Asia and elsewhere. This was true for
both clinical characteristics at baseline and for clinical outcomes.
However, the differences within Asia were not consistent and var-
ied for different characteristics. For example, patients in many
Asian countries were considerably younger than in Europe and
North America. However, patients in Japan and Taiwan were older
than in other Asian countries. There are two other large studies of
Asian patients with heart failure.8,14 The International Congestive
Heart Failure Study (INTER-CHF) included consecutive patients
with a clinical diagnosis of heart failure from outpatient clinics and
inpatient hospital wards at participating centres in India (n= 858),
China (n= 991) and South-East Asia (defined as Malaysia, and the
Philippines, n= 811), as well as patients in Africa (n=1294), Latin
America (n= 869), and the Middle East (n=1000).14 The average
age of patients in India, China, South-East Asia and Latin America,
was 56, 66, 57 and 67 years, respectively. However, the propor-
tion of patients with heart failure with preserved ejection fraction
(HFpEF) in these countries/regions varied considerably (47%, 63%,
61% and 47%, respectively), which is important for interpretation
of age as patients with HFpEF are generally older than patients with
HFrEF (and we studied only patients with HFrEF).15 Despite this, ..
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.. the age of patients in all these countries/regions were similar in the
two studies, except for China (patients in INTER-CHF in China
were older than in our study). The Asian Sudden Cardiac Death
in Heart Failure (ASIAN-HF) registry enrolled symptomatic HFrEF
in- or outpatients (with at least one episode of decompensated
heart failure in the previous 6months that resulted in a hospital
admission or was treated in an outpatient clinic) at 46 medical cen-
tres in 11 Asian countries/territories: China (n= 477)/Hong Kong
(n= 50), India (n=1436), Indonesia (n= 290), Japan (n= 540),
Korea (n= 317), Malaysia (n= 541), Philippines (n= 91), Singapore
(n= 1066), Taiwan (n= 274), and Thailand (n=194). The mean age
in these countries was 57.0/67.7, 57.8, 55.8, 64.9, 63.3, 57.4, 54.3,
60.7, 63.3, and 60.0 years, respectively.8 This age profile and rank-
ing within Asian countries was very similar to what we found in
our analysis. Genetic differences, stage of epidemiological transi-
tion, environmental factors, foetal programming, socioeconomic
status and other factors are thought to account for the increas-
ing prevalence and early development of cardiovascular disease in
low and middle-income countries. South Asians may be especially
prone to the premature development of cardiovascular diseases
because of their high frequency of insulin resistance, in part related
to pattern of fat distribution (abdominal obesity).16–18Atrial fib-
rillation was generally less frequent in Asian countries, especially
India, possibly because it is a particularly age-related condition, or
potentially because of ethnic or genetic differences.19,20 The par-
ticularly low prevalence of atrial fibrillation in India (2.5% in our
study) does not reflect ascertainment bias (as it was based on
electrocardiographic analysis) and was also found in the ASIAN-HF
registry (4.2%; frequency of atrial fibrillation was not reported in
INTER-CHF).8 Conversely, India and the Philippines differed from
other Asian countries in their high prevalence of diabetes (but not
higher BMI) whereas the Philippines and Taiwan had a higher preva-
lence of hypertension (but not a higher blood pressure) than other
Asian countries.
LVEF varied little among Asian countries or between Asia and
elsewhere whereas NT-proBNP varied much more, with several
Asian countries (Japan and Korea and, to a lesser extent, India
and Taiwan) having notably lower median concentrations than
elsewhere which in some of these countries may be attributed
to younger age, lower prevalence of atrial fibrillation and better
renal function.18,21 This did not seem to be explained by difference
in LVEF or NYHA class distribution and we know of no other
obvious explanation. Unfortunately, neither the ASIAN-HF registry
nor INTER-CHF reported NT-proBNP.8,14
Patients in Asian countries generally had a higher heart rate
than in Western Europe and North America and this was not
readily explicable by either prevalence of atrial fibrillation or
rate of beta-blocker treatment, although beta-blocker dosing may
be lower in Asian countries. Heart rate was not recorded in
INTER-CHF and, although the ASIAN-HF registry does not pro-
vide a direct comparison with other regions, heart rate was
generally higher than in similar studies from elsewhere.8,14
Interestingly, peripheral oedema was reported less frequently in
Asian patients and this was not obviously explained by differences
in diuretic therapy but could relate to climatic conditions or
MRA therapy, the use of which was higher in China and the
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
584 P. Dewan et al.
Ta
bl
e
4
C
ar
di
ov
as
cu
la
r
o
ut
co
m
es
o
fi
nt
er
es
t
ac
co
rd
in
g
to
co
un
tr
y
in
A
si
a
an
d
in
no
n-
A
si
an
re
gi
o
ns
W
es
te
rn
E
ur
o
pe
C
en
tr
al
/
E
as
te
rn
E
ur
o
pe
/
R
us
si
a
N
o
rt
h
A
m
er
ic
a
L
at
in
A
m
er
ic
a
C
hi
na
In
di
a
Ja
pa
n
K
o
re
a
P
hi
lip
pi
ne
s
Ta
iw
an
T
ha
ila
nd
(n
=
35
21
,
26
.7
%
)
(n
=
47
58
,
36
.1
%
)
(n
=
61
3,
4.
7%
)
(n
=
11
10
,
8.
4%
)
(n
=
83
3,
6.
3%
)
(n
=
13
90
,
10
.6
%
)
(n
=
20
9,
1.
6%
)
(n
=
22
3,
1.
7%
)
(n
=
22
3,
1.
7%
)
(n
=
19
9,
1.
5%
)
(n
=
95
,
0.
7%
)
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
Pr
im
ar
y
ou
tc
om
e
Ev
en
ts
,n
(%
)
94
9
(2
7.
0)
13
71
(2
8.
8)
18
1
(2
9.
5)
31
7
(2
8.
6)
29
0
(3
4.
8)
35
6
(2
5.
6)
69
(3
3.
0)
59
(2
6.
5)
51
(2
2.
9)
88
(4
4.
2)
31
(3
2.
6)
Ev
en
ts
pe
r
10
0
pa
tie
nt
-y
ea
rs
(9
5%
C
I)
10
.4
(9
.7
–
11
.0
)
12
.3
(1
1.
7
–
3.
0)
12
.8
(1
1.
0
–
4.
8)
12
.6
(1
1.
3
–
4.
0)
14
.9
(1
3.
3
–
6.
8)
10
.4
(9
.4
–
11
.6
)
10
.4
(8
.2
–
13
.2
)
9.
1
(7
.0
–
11
.7
)
11
.5
(8
.8
–
15
.2
)
17
.2
(1
4.
0
–
21
.2
)
13
.8
(9
.7
–
19
.6
)
U
na
dj
us
te
d
H
R
1.
00
(r
ef
)
1.
19
(1
.0
9
–
1.
29
)
1.
24
(1
.0
6
–
1.
46
)
1.
18
(1
.0
4
–
1.
34
)
1.
44
(1
.2
6
–
1.
64
)
1.
01
(0
.8
9
–
1.
14
)
1.
02
(0
.7
9
–
1.
30
)
0.
90
(0
.6
9
–
1.
17
)
1.
13
(0
.8
5
–
1.
50
)
1.
67
(1
.3
4
–
2.
08
)
1.
30
(0
.9
1
–
1.
85
)
A
dj
us
te
d
H
R
*
1.
00
(r
ef
)
1.
20
(1
.1
0
–
1.
32
)
1.
09
(0
.9
2
–
1.
28
)
1.
38
(1
.2
1
–
1.
57
)
1.
76
(1
.5
2
–
2.
02
)
1.
13
(0
.9
7
–
1.
30
)
1.
24
(0
.9
7
–
1.
58
)
1.
12
(0
.8
5
–
1.
46
)
1.
28
(0
.9
5
–
1.
74
)
1.
86
(1
.5
0
–
2.
30
)
1.
51
(1
.0
5
–
2.
18
)
H
ea
rt
fa
ilu
re
ho
sp
ita
liz
at
io
n
Ev
en
ts
,n
(%
)
64
3
(1
8.
3)
74
0
(1
5.
6)
13
7
(2
2.
3)
15
9
(1
4.
3)
19
3
(2
3.
2)
11
3
(8
.1
)
51
(2
4.
4)
36
(1
6.
1)
20
(9
.0
)
67
(3
3.
7)
23
(2
4.
2)
Ev
en
ts
pe
r
10
0
pa
tie
nt
-y
ea
rs
(9
5%
C
I)
7.
0
(6
.5
–
7.
6)
6.
7
(6
.2
–
7.
1)
9.
7
(8
.2
–
11
.4
)
6.
3
(5
.4
–
7.
4)
9.
9
(8
.6
–
11
.5
)
3.
3
(2
.8
–
4.
0)
7.
7
(5
.9
–
10
.2
)
5.
5
(4
.0
–
7.
7)
4.
5
(2
.9
–
7.
0)
13
.1
(1
0.
3
–
6.
7)
10
.2
(6
.8
–
15
.4
)
U
na
dj
us
te
d
H
R
1.
00
(r
ef
)
0.
90
(0
.8
1
–
1.
00
)
1.
36
(1
.1
3
–
1.
63
)
0.
82
(0
.6
9
–
0.
98
)
1.
35
(1
.1
5
–
1.
58
)
0.
44
(0
.3
6
–
0.
54
)
1.
16
(0
.8
7
–
1.
54
)
0.
82
(0
.5
9
–
1.
14
)
0.
58
(0
.3
7
–
0.
92
)
1.
88
(1
.4
6
–
2.
42
)
1.
40
(0
.9
3
–
2.
12
)
A
dj
us
te
d
H
R
*
1.
00
(r
ef
)
0.
91
(0
.8
1
–
1.
02
)
1.
14
(0
.9
4
–
1.
38
)
0.
93
(0
.7
8
–
1.
11
)
1.
65
(1
.3
8
–
1.
96
)
0.
51
(0
.4
1
–
0.
66
)
1.
45
(1
.0
9
–
1.
94
)
1.
01
(0
.7
1
–
1.
42
)
0.
64
(0
.4
0
–
1.
03
)
1.
94
(1
.4
7
–
2.
56
)
1.
63
(1
.0
6
–
2.
49
)
C
V
de
at
h
Ev
en
ts
,n
(%
)
53
7
(1
5.
3)
89
9
(1
8.
9)
98
(1
6.
0)
23
8
(2
1.
4)
18
0
(2
1.
6)
29
9
(2
1.
5)
29
(1
3.
9)
39
(1
7.
5)
42
(1
8.
8)
47
(2
3.
6)
21
(2
2.
1)
Ev
en
ts
pe
r
10
0
pa
tie
nt
-y
ea
rs
(9
5%
C
I)
5.
4
(4
.9
-5
.8
)
7.
4
(7
.0
–
7.
9)
6.
2
(5
.1
–
7.
5)
8.
8
(7
.7
–
10
.0
)
8.
2
(7
.1
–
9.
5)
8.
5
(7
.5
–
9.
5)
3.
8
(2
.6
–
5.
4)
5.
5
(4
.0
–
7.
5)
9.
0
(6
.7
–
12
.2
)
7.
7
(5
.8
–
10
.3
)
8.
6
(5
.6
–
13
.1
)
U
na
dj
us
te
d
H
R
1.
00
(r
ef
)
1.
42
(1
.2
–
1.
58
)
1.
20
(0
.9
7
–
1.
48
)
1.
62
(1
.3
9
–
1.
89
)
1.
56
(1
.3
2-
1.
84
)
1.
61
(1
.3
9
–
1.
85
)
0.
68
(0
.4
6
–
0.
98
)
1.
03
(0
.7
5
–
1.
42
)
1.
87
(1
.3
6
–
2.
57
)
1.
42
(1
.0
6
–
1.
92
)
1.
60
(1
.0
4
–
2.
46
)
A
dj
us
te
d
H
R
*
1.
00
(r
ef
)
1.
48
(1
.3
2
–
1.
66
)
1.
08
(0
.8
7
–
1.
34
)
1.
96
(1
.6
8
–
2.
29
)
1.
89
(1
.5
8
–
2.
27
)
1.
76
(1
.4
9
–
2.
09
)
0.
77
(0
.5
3
–
1.
12
)
1.
27
(0
.9
2
–
1.
78
)
2.
14
(1
.5
2
–
3.
00
)
1.
57
(1
.1
7
–
2.
10
)
1.
87
(1
.1
8
–
2.
96
)
A
ll-
ca
us
e
de
at
h
Ev
en
ts
,n
(%
)
71
7
(2
0.
4)
10
65
(2
2.
4)
13
1
(2
1.
4)
29
7
(2
6.
8)
19
2
(2
3.
0)
31
7
(2
2.
8)
35
(1
6.
7)
41
(1
8.
4)
48
(2
1.
5)
57
(2
8.
6)
24
(2
5.
3)
Ev
en
ts
pe
r
10
0
pa
tie
nt
-y
ea
rs
(9
5%
C
I)
7.
1
(6
.6
–
7.
7)
8.
8
(8
.3
–
9.
4)
8.
2
(6
.9
–
9.
8)
10
.9
(9
.8
–
12
.3
)
8.
8
(7
.6
–
10
.1
)
9.
0
(8
.0
–
10
.0
)
4.
6
(3
.3
–
6.
3)
5.
8
(4
.2
–
7.
8)
10
.3
(7
.8
–
13
.7
)
9.
4
(7
.2
–
12
.2
)
9.
8
(6
.6
–
14
.6
)
U
na
dj
us
te
d
H
R
+
1.
00
(r
ef
)
1.
25
(1
.1
4
–
1.
38
)
1.
19
(0
.9
9
–
1.
44
)
1.
55
(1
.3
5
–
1.
77
)
1.
23
(1
.0
5
–
1.
44
)
1.
26
(1
.1
0
–
1.
44
)
0.
61
(0
.4
3
–
0.
85
)
0.
79
(0
.5
8
–
1.
08
)
1.
55
(1
.1
6
–
2.
08
)
1.
30
(0
.9
9
–
1.
70
)
1.
37
(0
.9
2
–
2.
06
)
A
dj
us
te
d
H
R
*+
1.
00
(r
ef
)
1.
32
(1
.1
9
–
1.
46
)
1.
11
(0
.9
2
–
1.
35
)
1.
89
(1
.6
4
–
2.
18
)
1.
51
(1
.2
7
–
1.
79
)
1.
41
(1
.2
1
–
1.
64
)
0.
68
(0
.4
8
–
0.
96
)
0.
98
(0
.7
1
–
1.
36
)
1.
80
(1
.3
3
–
2.
44
)
1.
41
(1
.0
7
–
1.
85
)
1.
63
(1
.0
7
–
2.
48
)
C
I,
co
nfi
de
nc
e
in
te
rv
al
;C
V,
ca
rd
io
va
sc
ul
ar
;H
R
,h
az
ar
d
ra
tio
.
Bo
th
m
od
el
s
ad
ju
st
ed
fo
r
tr
ea
tm
en
t
an
d
re
gi
on
at
ba
se
lin
e.
H
R
de
no
te
s
su
b-
di
st
ri
bu
tio
n
H
R
w
ith
95
%
C
Iw
ith
in
br
ac
ke
ts
,e
xc
ep
t
w
he
re
+
de
no
te
s
H
R
.
* A
dj
us
te
d
fo
r
ra
nd
om
iz
ed
tr
ea
tm
en
t,
ag
e,
se
x,
he
ar
t
ra
te
,s
ys
to
lic
bl
oo
d
pr
es
su
re
,b
od
y
m
as
s
in
de
x,
le
ft
ve
nt
ri
cu
la
r
ej
ec
tio
n
fr
ac
tio
n,
N
ew
Yo
rk
H
ea
rt
A
ss
oc
ia
tio
n
cl
as
s,
N
-t
er
m
in
al
pr
o
br
ai
n
na
tr
iu
re
tic
pe
pt
id
e
an
d
es
tim
at
ed
gl
om
er
ul
ar
fil
tr
at
io
n
ra
te
.
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Heart failure in Asia 585
Figure 1 Cardiovascular outcomes of interest, shown as rates per 100 patient-years (unadjusted). (A) Primary composite outcome
(cardiovascular death or heart failure hospitalization). (B) Heart failure hospitalization. (C) Cardiovascular death. (D) All-cause death.
Philippines than in any other Asian country and higher than in any
other region, except Latin America (which also reported a low
prevalence of oedema). The strikingly low use of diuretics found
in the Philippines in the present study was supported by both
the ASIAN-HF registry and INTER-CHF. The high use of MRAs
in China (and the Philippines in the ASIAN-HF registry) was also
confirmed by each of these studies (and high use in Latin America
too by INTER-CHF).8,14 In China, this may be related to national
programmes to promote the use of spironolactone.22
There were other notable differences in treatment patterns,
with some Asian countries reporting much higher use of digoxin
than others (and elsewhere), despite a low prevalence of atrial
fibrillation. Digoxin use was not reported in the ASIAN-HF reg-
istry and was difficult to interpret in INTER-CHF given the mix of
patients with HFrEF and HFpEF. However, low use of anticoagulants
in India and China corroborated the low prevalence of atrial fibril-
lation in the two countries (neither ASIAN-HF nor INTER-CHF
reported use of anticoagulants). Device use was uniformly low in
Asia (as in Eastern Europe and Latin America), with only Japan
reporting above 10% use, likely reflecting economic considera-
tions as much as clinical ones. Device use was not reported in
INTER-CHF and was generally low in the ASIAN-HF registry, with
the exception of Japan.8,14
Appropriate versions of the KCCQ were available for four of
the seven Asian countries we studied (India, China, Japan and
Philippines). In one previous study, Indians had a higher mean
overall summary score (64.8) compared with Chinese who lived in
a number of Asian countries (mean score 60.1) and Japanese and ..
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.. Koreans (reported as a single group) had the highest score (67.3).23
While we found the highest median KCCQ clinical summary score
in patients enrolled in Japan, we found a reverse ranking for patients
in India and China compared with this prior study. Clearly, there
is a huge gap in our knowledge of patient reported outcomes in
different parts of Asia and compared with the rest of the world.
A particular strength of the present study is the availability of
information on long-term fatal and non-fatal outcomes. Here the
differences within Asia and between Asia and elsewhere were stark.
For example, the highest and lowest heart failure hospitalization
rates, globally, were found in Asian countries (Taiwan and India,
respectively). We know of no previous comparison of heart failure
hospitalization rates in ambulatory HFrEF patients in Asia (and
between Asia and elsewhere).
The low rate of hospitalization in India was especially striking,
being a third to half that in Europe and North America and about
a quarter of the rate in Taiwan. This was not explained by a
particularly high competing risk of death. Younger age, shorter
duration of heart failure and a higher KCCQ score (better quality
of life) may be relevant, as well as differences in access to, or
utilization of, hospital care in some countries (such as India).
This clearly has implications for clinical trials using heart failure
hospitalization as part of a composite outcome.
Conversely, the high hospitalization rates in other Asian coun-
tries were not explained by a lower risk of death. In fact, Asian
countries generally had high mortality rates with two notable
exceptions, namely Japan and Korea, which had the lowest and
second lowest mortality rates globally. These low rates reflect
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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the known long life expectancy in these two countries, especially
Japan.24 It is of interest to compare our findings in relation to mor-
tality with other studies which included patients from Asia. The
only study to do this that we know of was INTER-CHF, which
included consecutive patients with a clinical diagnosis of heart fail-
ure from outpatient clinics and inpatient hospital wards at partic-
ipating centres in India (n= 858), China (n= 991) and South-East
Asia (n= 811).14 The 1-year mortality was 23.3% in India, 7.3%
in China and 15.0% in South-East Asia (non-fatal outcomes were
not collected). However, the proportions of patients enrolled as an
in-patient (i.e. at higher risk of death) differed considerably (45%,
35%, and 23%, respectively) as did the proportion of patients with
HFrEF (53%, 27%, and 39%, respectively). Clearly, these differences
make comparison with our dataset impossible but highlight the
need for better understanding of mortality and morbidity rates
in Asia.
Our study has a number of strengths and weaknesses. Com-
parison of countries within Asia (and comparing countries in Asia
with other regions) is extremely complex, reflecting many influ-
ences including geography, climate and other environmental fac-
tors, diet and lifestyle, type of health care system, race/ethnicity,
cultural influences, genetics and economic considerations. Using
information from clinical trials also has disadvantages and advan-
tages. Patients in trials are selected and not necessarily represen-
tative of patients in the population in general, especially those living
in non-urban areas with inadequate access to health facilities. Com-
pared to epidemiological studies, however, the common inclusion
and exclusion criteria used in trials result in a more homogeneous
study population, overall. This allows a more ‘like-with-like’ com-
parison between countries. This difference from epidemiological
studies is highlighted by the mix of inpatients and outpatients and
patients with HFrEF and HFpEF in INTER-CHF.14 Patients in tri-
als are usually characterized in more detail than in epidemiological
studies as illustrated here by measurement of NT-proBNP, for
example. Event ascertainment in trials is also vigorous and con-
sistent across countries. However, our study has other limitations,
including the absence of information on patients from other key
regions, namely Africa and the Middle East.
In summary, although patient characteristics and outcomes vary
markedly between Asia and other global regions there are equally
striking variations among Asian countries (e.g. the highest and low-
est heart failure hospitalization rates, globally, were found in Asian
countries). These findings highlight the need to better understand
the explanations for the differences in mortality and morbidity
rates across Asia and have implications for the globalization of
clinical trials.
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